PL1891105T3 - Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe - Google Patents

Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe

Info

Publication number: PL1891105T3
Authority: PL; Poland
Prior art keywords: amino acids; oxm; analogues; effects; peptide
Prior art date: 2005-06-13

Application number

PL06744197T

Other languages

English (en)

Inventor

Stephen Robert Bloom

Mohammad Ali Ghatei

Original Assignee

Imperial Innovations Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-13

Filing date

2006-06-13

Publication date

2012-09-28

2005-06-13 Priority claimed from GB0511988A external-priority patent/GB0511988D0/en

2005-06-13 Priority claimed from GB0511998A external-priority patent/GB0511998D0/en

2005-06-13 Priority claimed from GB0511990A external-priority patent/GB0511990D0/en

2005-06-13 Priority claimed from GBGB0511986.2A external-priority patent/GB0511986D0/en

2006-02-08 Priority claimed from GB0602567A external-priority patent/GB0602567D0/en

2006-06-13 Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd

2012-09-28 Publication of PL1891105T3 publication Critical patent/PL1891105T3/pl

Links

PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title abstract 2
230000004634 feeding behavior Effects 0.000 title 1
229940121365 oxyntomodulin analogues Drugs 0.000 title 1
150000001413 amino acids Chemical class 0.000 abstract 7
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
108010011459 Exenatide Proteins 0.000 abstract 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 2
229960001519 exenatide Drugs 0.000 abstract 2
230000037406 food intake Effects 0.000 abstract 2
235000012631 food intake Nutrition 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Toxicology (AREA)
Pregnancy & Childbirth (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)

PL06744197T 2005-06-13 2006-06-13 Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe PL1891105T3 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GB0511988A GB0511988D0 (en)	2005-06-13	2005-06-13	Novel compounds and their effects on feeding behaviour
GB0511998A GB0511998D0 (en)	2005-06-13	2005-06-13	Novel compounds and their effects on feeding behaviour
GB0511990A GB0511990D0 (en)	2005-06-13	2005-06-13	Novel compounds and their effects on feeding behaviour
GBGB0511986.2A GB0511986D0 (en)	2005-06-13	2005-06-13	Novel compounds and their effects on feeding behaviour
GB0602567A GB0602567D0 (en)	2006-02-08	2006-02-08	Novel compounds and their effects on feeding behaviour
PCT/GB2006/002155 WO2006134340A2 (en)	2005-06-13	2006-06-13	Oxyntomodulin analogues and their effects on feeding behaviour
EP06744197A EP1891105B1 (en)	2005-06-13	2006-06-13	Oxyntomodulin analogues and their effects on feeding behaviour

Publications (1)

Publication Number	Publication Date
PL1891105T3 true PL1891105T3 (pl)	2012-09-28

Family

ID=37195703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06744197T PL1891105T3 (pl)	2005-06-13	2006-06-13	Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe

Country Status (16)

Country	Link
EP (2)	EP2351776A1 (pl)
JP (1)	JP2008543816A (pl)
KR (1)	KR101349808B1 (pl)
AT (1)	ATE553124T1 (pl)
AU (1)	AU2006258841B2 (pl)
BR (1)	BRPI0612069A2 (pl)
CA (1)	CA2612063A1 (pl)
CY (1)	CY1113014T1 (pl)
DK (1)	DK1891105T3 (pl)
ES (1)	ES2385093T3 (pl)
IL (1)	IL186802A0 (pl)
PL (1)	PL1891105T3 (pl)
PT (1)	PT1891105E (pl)
RU (1)	RU2485135C2 (pl)
SI (1)	SI1891105T1 (pl)
WO (1)	WO2006134340A2 (pl)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
PL205971B1 (pl)	2001-09-24	2010-06-30	Imp Innovations Ltd	Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
CA2628241C (en)	2005-11-07	2016-02-02	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
US9458444B2 (en)	2006-02-03	2016-10-04	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en)	2006-02-03	2019-07-16	Opko Biologics Ltd.	Methods of treatment with long-acting growth hormone
US8946155B2 (en)	2006-02-03	2015-02-03	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
EP2471810A1 (en) *	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
TWI428346B (zh) *	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
CN101578102B (zh) *	2007-01-05	2013-07-17	印第安纳大学研究及科技有限公司	在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
MX2009008241A (es)	2007-02-15	2009-10-08	Univ Indiana Res & Tech Corp	Co-agonistas de receptor de glucagon/glp-1.
EP2025684A1 (en) *	2007-08-15	2009-02-18	Zealand Pharma A/S	Glucagon analogues
JP5385266B2 (ja) *	2007-06-15	2014-01-08	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP5771005B2 (ja)	2007-10-30	2015-08-26	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
CA2707861A1 (en)	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Glucagon antagonists
TWI474835B (zh)	2008-06-17	2015-03-01	Univ Indiana Res & Tech Corp	用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
TWI541023B (zh)	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
EP2300037B1 (en)	2008-06-17	2016-03-30	Indiana University Research and Technology Corporation	Glucagon/glp-1 receptor co-agonists
JO2870B1 (en)	2008-11-13	2015-03-15	ميرك شارب اند دوهم كورب	Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
AU2008365557A1 (en)	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
MX2011006314A (es)	2008-12-15	2011-09-22	Zealand Pharma As	Analogos de glucagon.
EA020537B1 (ru)	2008-12-15	2014-11-28	Зилэнд Фарма А/С	Аналоги глюкагона
PL2370462T3 (pl)	2008-12-15	2015-01-30	Zealand Pharma As	Analogi glukagonu
RU2550696C2 (ru)	2008-12-19	2015-05-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Основанные на амидах пролекарства пептидов глюкагонового надсемейства
WO2010096052A1 (en) *	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
WO2010148089A1 (en)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
US12203113B2 (en)	2009-07-09	2025-01-21	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
AP3329A (en)	2009-07-13	2015-06-30	Zealand Pharma As	Acylated glucagon analogues
BR112012004335A8 (pt)	2009-09-02	2016-06-21	Merck Sharp & Dohme	Composto, composição farmacêutica, e, uso do composto.
RU2524204C2 (ru) *	2009-11-30	2014-07-27	Российская Федерация, От Имени Которой Выступает Министерство Промышленности И Торговли Российской Федерации	Оксинтомодулин человека, его применение, лекарственный препарат на его основе и способ применения препарата для лечения и профилактики гипергликемии
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
JO2976B1 (en)	2009-12-22	2016-03-15	ايلي ليلي اند كومباني	Axentomodulin polypeptide
AR079344A1 (es) *	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
EP2528618A4 (en)	2010-01-27	2015-05-27	Univ Indiana Res & Tech Corp	GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
EP2538783B1 (en)	2010-02-22	2016-06-01	Merck Sharp & Dohme Corp.	Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CA2797095A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011143208A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
US8980929B2 (en)	2010-05-21	2015-03-17	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
MX2012014576A (es)	2010-06-24	2013-02-21	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida.
KR20130086343A (ko)	2010-06-24	2013-08-01	질랜드 파마 에이/에스	글루카곤 유사체
WO2012088116A2 (en)	2010-12-22	2012-06-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity
SG192038A1 (en)	2011-01-20	2013-08-30	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues
WO2012150503A2 (en)	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en)	2011-05-10	2012-11-15	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
US10166295B2 (en)	2011-06-02	2019-01-01	Opko Biologics Ltd.	Pegylated OXM variants
UA126465C2 (uk) *	2011-06-10	2022-10-12	Ханмі Сайенс Ко., Лтд.	Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
PL2721062T3 (pl) *	2011-06-17	2019-05-31	Hanmi Science Co Ltd	Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie
CN103857408B (zh)	2011-06-22	2017-04-12	印第安那大学科技研究公司	胰高血糖素/glp‑1受体协同激动剂
MX2013015168A (es)	2011-06-22	2014-03-31	Univ Indiana Res & Tech Corp	Co-agonista del receptor de glucagon/glp-1.
EP2729493B1 (en)	2011-07-04	2020-06-10	IP2IPO Innovations Limited	Novel compounds and their effects on feeding behaviour
MY167234A (en)	2011-09-23	2018-08-14	Novo Nordisk As	Novel glucagon analogues
HK1198810A1 (en)	2011-11-17	2015-06-12	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
KR20140114845A (ko)	2011-12-23	2014-09-29	질랜드 파마 에이/에스	글루카곤 유사체
US20150057220A1 (en)	2012-04-16	2015-02-26	Kaneq Pharma Inc.	Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
US9522945B2 (en)	2012-04-19	2016-12-20	Opko Biologics Ltd.	Long-acting oxyntomodulin variants and methods of producing same
NZ702333A (en)	2012-05-03	2017-06-30	Zealand Pharma As	Gip-glp-1 dual agonist compounds and methods
PE20150181A1 (es) *	2012-06-04	2015-02-28	Opko Biolog Ltd	Variantes de oxm pegilada
SG11201407860PA (en) *	2012-06-14	2014-12-30	Sanofi Sa	Exendin-4 peptide analogues
US9340600B2 (en)	2012-06-21	2016-05-17	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
MX356957B (es)	2012-07-23	2018-06-20	Zealand Pharma As	Analogos del glucagon.
KR101968344B1 (ko) *	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PT2916819T (pt)	2012-11-06	2019-10-28	Hanmi Pharm Ind Co Ltd	Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina.
SG10202010383YA (en)	2012-11-20	2020-11-27	Opko Biologics Ltd	Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
MY174727A (en)	2013-04-18	2020-05-11	Novo Nordisk As	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
LT3057984T (lt)	2013-10-17	2018-12-27	Zealand Pharma A/S	Acilinti gliukagono analogai
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
AU2014345569B2 (en)	2013-11-06	2020-08-13	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CN112043835B (zh)	2013-12-06	2022-10-21	韩捷	用于含氮和羟基的药物的生物可逆引入基团
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
WO2015086731A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086732A1 (en) *	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
AR098614A1 (es)	2013-12-18	2016-06-01	Lilly Co Eli	Compuesto para el tratamiento de hipoglicemia severa
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US10570184B2 (en)	2014-06-04	2020-02-25	Novo Nordisk A/S	GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN104926934B (zh) *	2014-09-23	2016-11-09	蒋先兴	胃泌酸调节素类似物
CA3093383A1 (en)	2014-10-24	2016-04-28	Merck Sharp & Dohme Corp.	Co-agonists of the glucagon and glp-1 receptors
RU2716985C2 (ru)	2014-10-29	2020-03-17	Зилэнд Фарма А/С	Соединения-агонисты gip и способы
EA201791275A1 (ru)	2014-12-10	2017-12-29	Опко Байолоджикс Лтд.	Способы получения ctp-модифицированных полипептидов длительного действия
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
JP6989385B2 (ja)	2015-04-16	2022-01-05	ジーランドファーマアクティーゼルスカブ	アシル化グルカゴン類似体
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
IL301728A (en)	2015-06-19	2023-05-01	Opko Biologics Ltd	Long-term coagulation factors and methods for their preparation
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3359191A4 (en)	2015-10-05	2019-05-29	Merck Sharp & Dohme Corp.	ANTIBODY PEPTIDE CONJUGATES WITH AGONISTEACTIVITY ON GLUCAGON RECEPTORS AND GLUCAGON-LIKE PEPTIDE-1
WO2017074798A2 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Long-acting co-agonists of the glucagon and glp-1 receptors
EP3394091A4 (en)	2015-12-09	2019-12-18	Merck Sharp & Dohme Corp.	CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
HUE064463T2 (hu)	2016-07-11	2024-03-28	Opko Biologics Ltd	Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
TW201832783A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
AR110301A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
AR110300A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
CA3220650A1 (en)	2017-09-25	2019-03-28	Merck Sharp & Dohme Llc	Long-acting co-agonists of the glucagon and glp-1 receptors
JP2018090636A (ja) *	2018-03-15	2018-06-14	インペリアル・イノベイションズ・リミテッド	新規化合物及び摂食行動に対するそれらの効果
CN112543763B (zh)	2018-04-10	2024-11-05	赛诺菲-安万特德国有限公司	从固相裂解固相结合肽的方法
ES2928207T5 (en)	2018-04-10	2026-02-16	Sanofi Aventis Deutschland	Lixisenatide synthesis with capping
TW202015735A (zh)	2018-05-30	2020-05-01	法商賽諾菲公司	包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
US12441776B2 (en)	2018-11-30	2025-10-14	Eirgen Pharma Ltd.	Oxyntomodulin peptide analog formulations
CA3123979A1 (en)	2018-12-21	2020-06-25	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
EP3842449A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842060A1 (en)	2019-12-23	2021-06-30	Merck Sharp & Dohme Corp.	Stapled lactam co-agonists of the glucagon and glp-1 receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
CA1257199A (en)	1986-05-20	1989-07-11	Paul Y. Wang	Preparation containing bioactive macromolecular substance for multi-months release in vivo
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5907030A (en)	1995-01-25	1999-05-25	University Of Southern California	Method and compositions for lipidization of hydrophilic molecules
US5962270A (en)	1996-02-06	1999-10-05	Bionebraska, Inc.	Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6093692A (en)	1997-09-25	2000-07-25	The University Of Southern California	Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr)	1998-02-10	2000-03-24	Atochem Elf Sa	Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en)	1998-04-23	1999-11-30	Medtronic, Inc.	Implantable device
PL205713B1 (pl) *	1998-12-07	2010-05-31	Sod Conseils Rech Applic	Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
US6436091B1 (en)	1999-11-16	2002-08-20	Microsolutions, Inc.	Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
CN1220702C (zh) *	2003-07-30	2005-09-28	北京中科亚光生物科技有限公司	促胰岛素分泌肽及其用途
WO2005035761A1 (en) *	2003-10-16	2005-04-21	Compugen Ltd.	Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US8921528B2 (en)	2004-06-01	2014-12-30	Domantis Limited	Bispecific fusion antibodies with enhanced serum half-life

2006
- 2006-06-13 CA CA002612063A patent/CA2612063A1/en not_active Abandoned
- 2006-06-13 ES ES06744197T patent/ES2385093T3/es active Active
- 2006-06-13 EP EP10195787A patent/EP2351776A1/en not_active Withdrawn
- 2006-06-13 PT PT06744197T patent/PT1891105E/pt unknown
- 2006-06-13 RU RU2008100238/04A patent/RU2485135C2/ru not_active IP Right Cessation
- 2006-06-13 SI SI200631355T patent/SI1891105T1/sl unknown
- 2006-06-13 AU AU2006258841A patent/AU2006258841B2/en not_active Ceased
- 2006-06-13 WO PCT/GB2006/002155 patent/WO2006134340A2/en not_active Ceased
- 2006-06-13 PL PL06744197T patent/PL1891105T3/pl unknown
- 2006-06-13 JP JP2008516398A patent/JP2008543816A/ja not_active Withdrawn
- 2006-06-13 KR KR1020087000871A patent/KR101349808B1/ko not_active Expired - Fee Related
- 2006-06-13 AT AT06744197T patent/ATE553124T1/de active
- 2006-06-13 DK DK06744197.2T patent/DK1891105T3/da active
- 2006-06-13 BR BRPI0612069-5A patent/BRPI0612069A2/pt not_active IP Right Cessation
- 2006-06-13 EP EP06744197A patent/EP1891105B1/en active Active
2007
- 2007-10-21 IL IL186802A patent/IL186802A0/en unknown
2012
- 2012-06-27 CY CY20121100570T patent/CY1113014T1/el unknown

Also Published As

Publication number	Publication date
KR20080039375A (ko)	2008-05-07
DK1891105T3 (da)	2012-07-16
BRPI0612069A2 (pt)	2009-01-20
WO2006134340A9 (en)	2009-03-05
AU2006258841A1 (en)	2006-12-21
CA2612063A1 (en)	2006-12-21
JP2008543816A (ja)	2008-12-04
KR101349808B1 (ko)	2014-02-13
RU2008100238A (ru)	2009-07-20
PT1891105E (pt)	2012-06-27
WO2006134340A2 (en)	2006-12-21
ATE553124T1 (de)	2012-04-15
AU2006258841B2 (en)	2012-05-03
EP2351776A1 (en)	2011-08-03
SI1891105T1 (sl)	2012-07-31
EP1891105A2 (en)	2008-02-27
WO2006134340A3 (en)	2007-06-28
HK1109906A1 (en)	2008-06-27
ES2385093T3 (es)	2012-07-18
CY1113014T1 (el)	2016-04-13
RU2485135C2 (ru)	2013-06-20
EP1891105B1 (en)	2012-04-11
IL186802A0 (en)	2008-02-09

Publication	Publication Date	Title
SI1891105T1 (sl)	2012-07-31	Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
MXPA06001283A (es)	2006-04-11	Derivados de insulina novedosos.
ZA201001054B (en)	2011-04-28	Peptide with reduced dimer formation
NZ600690A (en)	2014-03-28	Fkbp-l and uses thereof
MXPA06003474A (es)	2006-06-05	Agonistas de receptores de melanocortina.
EA201170878A1 (ru)	2012-01-30	Полипептиды с ксиланазной активностью
WO2009007714A3 (en)	2009-04-02	Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
WO2007056362A3 (en)	2009-04-23	Glucagon analogs exhibiting physiological solubility and stability
UA102506C2 (ru)	2013-07-25	Селективные аналоги глюкагоноподобного пептида-2 (glp-2)
NO20082345L (no)	2008-05-23	Selektive VPAC2 reseptorpeptidagonister
WO2005058959A3 (en)	2005-12-15	Treatment of viral infections
WO2008087224A3 (en)	2008-09-25	Mutated netrin 4, fragments thereof and uses thereof as drugs
WO2007101146A3 (en)	2007-12-21	Selective vpac2 receptor peptide agonists
WO2007133828A3 (en)	2009-01-29	Selective vpac2 receptor peptide agonists
WO2008005527A8 (en)	2008-07-24	Glucagon-like peptides and uses thereof
ZA200901342B (en)	2010-11-24	Cytokine derivatives
WO2006023356A3 (en)	2006-05-18	Selective vpac2 receptor peptide agonists
ATE389670T1 (de)	2008-04-15	Selektive peptidische agonisten des vpac2- rezeptors
SG146640A1 (en)	2008-10-30	Isolated photoprotein mtclytin, and use thereof
ATE467643T1 (de)	2010-05-15	Peptide mit proliferationshemmender wirkung
ATE412010T1 (de)	2008-11-15	Selektive peptidische agonisten des vpac2- rezeptors
WO2007101948A3 (fr)	2007-11-15	Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus
GB0522295D0 (en)	2005-12-07	Peptides and uses thereof
GB0520872D0 (en)	2005-11-23	Onion flavour compounds and use
TW200716177A (en)	2007-05-01	Isolated photoprotein aqdecay, and its use